New Zealand expects coronavirus vaccine doses for 750,000 people by early 2021 from Pfizer and BioNTech.
Investors in Pfizer Inc (NYSE: PFE) and BioNTech SE ADR (NASDAQ: BNTX) are expecting near future good returns, putting in mind New Zealand have signed a deal to purchase 1.5 million coronavirus vaccine doses by early next year.
Pfizer and BioNTech Stocks Analysis
During Monday’s Asian trading session, Pfizer stocks were trading around $36.76, 0.08% down from Friday’s close. As for BioNTech stocks, they were trading around $89.47, 0.48% up from Friday’s close.
Notably, although both companies have collaborated to develop a vaccine against the coronavirus, BioNTech stocks have rallied a lot more than Pfizer stocks during the pandemic.
Whereas BioNTech stocks have surpassed the February-March market crash, Pfizer stocks are still struggling to fully recover from the crisis.
According to metrics provided by MarketWatch, Pfizer stocks were up 1.88% in the past twelve months through October 12. However, they had dropped 6.10% year to date through Monday. They had, however, jumped 8.75% and 2% in the past three months and one month respectively through Monday.
At the time of writing, Pfizer had a market capitalization of approximately $204.44 billion with 5.56 billion outstanding shares. Having been analyzed by 18 credible Wall Street analysts, Pfizer stocks received an average of Over rating.
On the other hand, BioNTech stocks were up 598.35% in the past twelve months through Monday. They had managed to climb 162.82% year to date. They had jumped approximately 14.48% in the past three months. And notably, they had added 31.95% and 10.33% in the past one month and five days respectively.
At the time of writing, BioNTech had a market capitalization of approximately $21.21 billion with 238.17 million outstanding shares.
Perhaps due to the fewer outstanding shares in comparison to Pfizer, BioNTech shares are poised to experience a bigger jump than the former if the market conditions prevail.
Notably, after 11 credible Wall Street analysts critically analyzed BioNTech stocks, they on average gave them an Over rating.
Vaccine Candidate
The two companies have been pushing for their coronavirus vaccine candidate to be approved by different global jurisdictions.
As they go through phase 3 of clinical trials, the two companies began submitting clinical data to the European Medicines Agency for approval. In addition, they are working to get approval from the United States FDA.
New Zealand expects vaccine doses for 750,000 people by early 2021 from Pfizer and BioNTech. However, the financial terms of the deal have not been disclosed to the public.
As the world total coronavirus infected number tops 37.7 million people, New Zealand has managed to tame the infection rate since the virus was announced a global pandemic. New Zealand has only reported 1,871 infected people, whereby 1,801 of them have recovered and only 25 reported fatalities. The country had struck lockdown measures to control the spread.
next